The European Society of Cardiology congress revealed key advances in cardiovascular and lipid-lowering therapies, including Novartis’ Leqvio showing rapid lipid reductions in high-risk patients and Alnylam planning a Phase 3 cardiovascular outcomes trial for zilebesiran despite mid-stage blood pressure data shortfalls. Cytokinetics’ cardiac myosin inhibitor aficamten demonstrated clinical benefits over beta blockers in hypertrophic cardiomyopathy, with potential to become the new standard of care. Separately, BeOne Medicines advanced sonrotoclax for rare B cell lymphoma by meeting early response endpoints, highlighting ongoing innovation in oncology therapeutics.